title: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
abstract: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter by computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients-especially those with large-cell NHL-who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval by regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available.
authors.affiliation: National Cancer Institute, Bethesda, MD 20892, USA. chesonb@ctep.nci.nih.gov
authors.forename: B D
authors.initials: BD
authors.lastname: Cheson
authors.forename: S J
authors.initials: SJ
authors.lastname: Horning
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: M A
authors.initials: MA
authors.lastname: Shipp
authors.forename: R I
authors.initials: RI
authors.lastname: Fisher
authors.forename: J M
authors.initials: JM
authors.lastname: Connors
authors.forename: T A
authors.initials: TA
authors.lastname: Lister
authors.forename: J
authors.initials: J
authors.lastname: Vose
authors.forename: A
authors.initials: A
authors.lastname: Grillo-López
authors.forename: A
authors.initials: A
authors.lastname: Hagenbeek
authors.forename: F
authors.initials: F
authors.lastname: Cabanillas
authors.forename: D
authors.initials: D
authors.lastname: Klippensten
authors.forename: W
authors.initials: W
authors.lastname: Hiddemann
authors.forename: R
authors.initials: R
authors.lastname: Castellino
authors.forename: N L
authors.initials: NL
authors.lastname: Harris
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: W
authors.initials: W
authors.lastname: Carter
authors.forename: R
authors.initials: R
authors.lastname: Hoppe
authors.forename: G P
authors.initials: GP
authors.lastname: Canellos
mesh_terms: D002986:Clinical Trials as Topic / Q000592:standards*; D003131:Combined Modality Therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D016896:Treatment Outcome